tiprankstipranks
Pfizer (PFE)
NYSE:PFE

Pfizer Stock Forecast & Price Target

22,236 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
11Ratings
5 Buy
6 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Pfizer
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PFE Stock Price Prediction

Average Price Target

$61.73
▲(38.84% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is $61.73 with a high forecast of $109.00 and a low forecast of $44.00. The average price target represents a 38.84% change from the last price of $44.46.
Highest Price Target$109.00Average Price Target$61.73Lowest Price Target$44.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Morgan Stanley
$49.00
Hold
10.21%
Upside
Reiterated
Pfizer (PFE) PT Lowered to $49 at Morgan StanleyMorgan Stanley analyst Terrance Flynn lowered the price target on Pfizer (NYSE: PFE) to $49.00 (from $52.00) while maintaining a Equalweight rating.
J.P. Morgan
$57.00
Hold
28.21%
Upside
Reiterated
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Fate Therapeutics (NASDAQ: FATE) and Kezar Life Sciences (NASDAQ: KZR)
Bank of America Securities
$70.00
Buy
57.44%
Upside
Reiterated
Pfizers (PFE) Etrasimod Call Highlights Unmet Need Opportunity - BofA SecuritiesThe analyst stated "Weve continued to argue that Pfizer should turn its COVID-19 windfall into long-term franchises through aggressive MA, and we think Pfizers acquisition of Arena (our take on the deal) is likely a first of many shots on goal. Indeed, Pfizer is continuing to leverage its strategic options to reengage investors and drive top-line growth, in our view, which together with attractive share prices justifies our Buy rating."
Mizuho Securities
$55.00
Hold
23.71%
Upside
Reiterated
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pfizer (NYSE: PFE) and Concert Pharma (NASDAQ: CNCE)
Evercore ISI
Buy
Reiterated
Analysts Have Conflicting Sentiments on These Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Pfizer (NYSE: PFE) and Enanta Pharmaceuticals (NASDAQ: ENTA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

PFE Stock Forecast FAQ

What is PFE’s average 12-month price target, according to analysts?
Based on analyst ratings, Pfizer’s 12-month average price target is $61.73.
    What is PFE’s upside potential, based on the analysts’ average price target?
    Pfizer has 38.84% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PFE a Buy, Sell or Hold?
          Pfizer has a conensus rating of Moderate Buy which is based on 5 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Pfizer’s price target?
            The average price target for Pfizer is $61.73. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $109.00 ,the lowest forecast is $44.00. The average price target represents 38.84% Increase from the current price of $44.46.
              What do analysts say about Pfizer?
              Pfizer’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis